menu
    • menu
    [{"orgOrder":0,"company":"Orlance","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Orlance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Orlance \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Orlance \/ National Institutes of Health"},{"orgOrder":0,"company":"Orlance","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"MACH-1-based Vaccine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Orlance","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Orlance \/ National Institutes of Health","highestDevelopmentStatusID":"14","companyTruncated":"Orlance \/ National Institutes of Health"}]

    Find Clinical Drug Pipeline Developments & Deals by Orlance

    Menu

    Orlance

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Orlance

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Orlance

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MACH-1-based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $3.3 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Orlance Awarded $3.3M NIH Grant for MACH-1™ Enhanced Influenza Vaccine

                            Details : The proceeds will enable Orlance to leverage its innovative MACH-1 powdered vaccine and immunotherapy platform to address both seasonally-changing and highly-conserved influenza immunogens.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            October 10, 2024

                            Lead Product(s) : MACH-1-based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $3.3 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Orlance

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Orlance

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $3.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Orlance Inc. Awarded Pivotal $3M NIH SBIR Grant for Advancing MACH-1™ Needle-Free, Powdered Universal Influe...

                            Details : The net proceeds will be used to advance company's needle-free MACH-1 delivery platform and a universal influenza vaccine designed to protect from the annual flu and future pandemics toward Phase 1 clinical trials.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            November 28, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $3.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth